Observational study on lung cancer patients in Canada
Pan-Canadian Lung Cancer Observational Study (PALEOS)
This study is looking at lung cancer patients in Canada to see how different treatments work and what outcomes they have based on specific genetic changes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 25000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | William Osler Health System Academic / other |
| Locations | 1 site (Brampton, Ontario) |
| Trial ID | NCT04706754 on ClinicalTrials.gov |
What this trial studies
This multicenter observational study aims to collect data on lung cancer patients across Canada, focusing initially on specific molecular alterations such as ALK, EGFR, and ROS1. By utilizing both retrospective and prospective methods, the study seeks to understand the natural history, treatment patterns, and outcomes of various lung cancer subgroups. The goal is to generate real-world data that reflects how treatments and outcomes translate from clinical trials to everyday practice. The study will expand to include other rare molecular alterations in its second year.
Who should consider this trial
Good fit: Ideal candidates are Canadian adults aged 18 years or older who have been diagnosed with lung cancer since 2006.
Not a fit: Patients who are unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the treatment and management of lung cancer, leading to improved patient outcomes.
How similar studies have performed: Other studies have successfully utilized similar observational approaches to gather real-world data on cancer treatment and outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: • Adults aged 18 years or older having a documented lung cancer diagnosis since 2000. Exclusion Criteria: • Patients that decline to provide informed consent.
Where this trial is running
Brampton, Ontario
- Milena (Lynn) Vicente — Brampton, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Parneet Cheema, MD — William Osler Health System
- Study coordinator: Lynn Vicente
- Email: lynn.vicente@williamoslerhs.ca
- Phone: 4164362556
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.